Navigation Links
Therapure Biopharma Inc. opens for business with first client contracts
Date:9/3/2008

TORONTO, Sept. 3 /PRNewswire/ - Therapure Biopharma Inc., a Canadian biopharmaceutical company, announced that it is open for business and has its first contracts with customers in biopharmaceutical development and manufacturing.

Located in Mississauga, Ontario, just 30 minutes from Toronto's Pearson International Airport, Therapure Biopharma provides clients with customized solutions for the development and manufacture of complex biological products. Leveraging its unique and flexible, 130,000 square foot cGMP manufacturing facility, its extensive quality systems, and the dedication of its highly experienced staff, Therapure Biopharma is able to develop effective and innovative solutions to advance therapeutic proteins from the lab to the market.

"We are more than just a contract manufacturing organization (CMO)," said Thomas G. Wellner, President and Chief Executive Officer. "The Company's scientific, manufacturing, and downstream purification expertise, combined with an intimate understanding of advanced biology, complex proteins, and the regulatory requirements for biological drugs, enables us to be a drug development partner with our clients."

Therapure Biopharma offers a wide range of value-added services covering all aspects of protein production so that the scale-up to commercial manufacture will not be a barrier to success. The Company's qualified staff has solved many of the manufacturing challenges facing clients, and the Company will partner with clients to solve their challenges. Many dynamic companies have access to novel, high-value protein-based products that are ready for commercialization but do not have the capabilities to move ahead alone. Therapure Biopharma can help by applying a deep understanding of the market and the business opportunities for protein-based therapeutics.

"We understand the complex regulatory processes for the registration of biological products and have established quality-based cGMP compliant manufacturing processes. We also understand and appreciate the confidential nature of your business and desire a long-term relationship," said Mr. Wellner. "Therapure Biopharma is your one-stop shop for pilot and commercial scale protein/API production, processing, filling, and finishing. We can address your scale-up challenges from bench to commercial scale. Partner with us and we will apply our expertise and proprietary technology to advance your products effectively."

Let Therapure Biopharma be a partner in bringing your biopharmaceutical products to the world. For more information, please visit the company's website at http://www.therapurebio.com.


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
4. Ondine Biopharma Announces Second Quarter 2008 Financial Results
5. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
8. ARCA biopharma Appoints James Carr as Vice President of Marketing
9. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017 Synthetic Biologics, Inc. (NYSE ... the microbiome to protect and restore the health of patients, intends ... December 31, 2016 on Thursday, March 2, 2017, and to host ... dial-in information for the call is as follows: U.S. ... ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... to announce that Dr. Trevor Heritage has joined its executive team to lead ... system designed to provide insights to help improve the diagnosis and treatment of ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 ... announced that apatorsen results from two randomized Phase 2 clinical ... (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 th - ... data from trials in bladder and prostate cancers demonstrated apatorsen ... with standard-of-care treatments. ...
(Date:2/21/2017)... Feb 21, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 12.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):